BCL2L1 and neoplasm: The <i>in vitro</i> findings in E0771 cells were validated through studies conducted in vivo in immunocompetent mice implanted with E0771-derived tumors where both drugs reduced tumor progression and shifted cells to apoptosis in sequential combination with doxorubicin.<h4>Conclusions</h4>These findings suggest that administration of venetoclax has the potential to enhance suppression of doxorubicin-exposed cancer cells, and that it may have potential as that of Bcl-xL-targeting agents.